<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000546734"><TermName>tyrosine kinase inhibitor BIBF 1120</TermName><TermPronunciation>(TY-ruh-seen KY-nays in-HIH-bih-ter...)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of some types of cancer. Tyrosine kinase inhibitor BIBF 1120 blocks enzymes needed for cells to grow, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called BIBF 1120.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718790" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tyrosine kinase inhibitor BIBF 1120&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718791" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;inhibidor de la tirosina cinasa BIBF 1120&quot;" language="es" id="_4"/><SpanishTermName>inhibidor de la tirosina cinasa BIBF 1120</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de algunos tipos de cáncer. El inhibidor de la tirosina cinasa BIBF 1120 impide la acción de las enzimas que las células necesitan para crecer y podría prevenir la formación de vasos sanguíneos  nuevos que los tumores necesitan para formarse. Es un tipo de inhibidor de la tirosina cinasa y un tipo de antiangiogénico. También se llama BIBF 1120.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-05-04</DateFirstPublished><DateLastModified>2009-04-21</DateLastModified></GlossaryTerm>
